Central Trust Company’s IGC Pharma IGC Stock Holding History

Central Trust Company’s Portfolio IGC Stock Details IGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-900	Closed	-$360	–	1430
2024 Q1	$360	Buy	+900	New	+$279	﹤0.01%	1351

Other funds holding IGC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Dearborn Partners Chicago, Illinois $1.85B AUM 6.59% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return

Central Trust Company's IGC Position: Q2 2024 in Review

Central Trust Company sold out of IGC Pharma (IGC) in Q2 2024, closing a stake of 900 shares — an estimated $360 sold.

Central Trust Company first reported a position in IGC in Q1 2024 and held it in 1 quarter. The position peaked at $360 in Q1 2024. 25 funds tracked by Wall St. Rank hold IGC as of Q2 2024.

Central Trust Company reported no remaining IGC Pharma position as of Q2 2024 after selling out during the quarter.
Central Trust Company sold 900 IGC Pharma shares in Q2 2024, an estimated $360.
Central Trust Company first reported a position in IGC Pharma in Q1 2024 and held it in 1 quarter.
Central Trust Company's IGC Pharma position peaked at $360 in Q1 2024.
25 funds tracked by Wall St. Rank held IGC Pharma as of Q2 2024.

Based on Central Trust Company's 13F filing for Q2 2024, filed 5 Aug 2024.